Cargando…

Comparison of different regimens with or without fluoroquinolone in isoniazid-resistant tuberculosis: A multicenter cohort study

In 2018, the World Health Organization recommended a 6-month four-drug regimen (rifampicin, ethambutol, pyrazinamide, and levofloxacin) for the treatment of isoniazid-monoresistant tuberculosis. However, the regimen had very low certainty. This cohort study assessed the impact of fluoroquinolone use...

Descripción completa

Detalles Bibliográficos
Autores principales:	Min, Jinsoo, Kim, Hyung Woo, Kang, Ji Young, Kim, Sung Kyoung, Kim, Jin Woo, Kim, Yong Hyun, Yoon, Hyoung Kyu, Lee, Sang Haak, Kim, Ju Sang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387806/ https://www.ncbi.nlm.nih.gov/pubmed/35980991 http://dx.doi.org/10.1371/journal.pone.0273263

Ejemplares similares

Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study
por: Lee, Eung Gu, et al.
Publicado: (2020)

Delphi Survey on the Current and Future Korean Guidelines for Isoniazid-Monoresistant Tuberculosis
por: Seo, Wan, et al.
Publicado: (2023)

Tuberculosis: Republic of Korea, 2021
por: Min, Jinsoo, et al.
Publicado: (2023)

A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis
por: Jung, Jin Ah, et al.
Publicado: (2015)

Prediction of treatment failure and compliance in patients with tuberculosis
por: Koo, Hyeon-Kyoung, et al.
Publicado: (2020)

Emerging Enterococcus isolates in postoperative endophthalmitis by selection pressure of fluoroquinolones: an 11-year multicenter and experimental study
por: Kim, Jiyeun Kate, et al.
Publicado: (2020)

The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis
por: Lee, Hyun Woo, et al.
Publicado: (2016)

Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance
por: Stagg, Helen R., et al.
Publicado: (2019)

Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital
por: Chung, Sung Jun, et al.
Publicado: (2020)

The association between eosinophilic exacerbation and eosinophilic levels in stable COPD
por: Kang, Hye Seon, et al.
Publicado: (2021)

Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy
por: Sung, Yoon-Kyoung, et al.
Publicado: (2018)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

One Step toward a Low Tuberculosis-Burden Country: Screening for Tuberculosis Infection among the Immigrants and Refugees
por: Kim, Hyung Woo, et al.
Publicado: (2020)

Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD
por: Kang, Hye Seon, et al.
Publicado: (2016)

Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy
por: Kim, Hyung Woo, et al.
Publicado: (2018)

Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin
por: Pillay, Samantha, et al.
Publicado: (2022)

Deaths from tuberculosis: differences between tuberculosis-related and non-tuberculosis-related deaths
por: Jeong, Yun-Jeong, et al.
Publicado: (2023)

790. The Efficacy of the Interferon-γ Releasing Assay-Based Isoniazid Treatment for Preventing Active Tuberculosis in Kidney Transplant Recipients: A Quasi-experimental Study
por: Kim, Hae-In, et al.
Publicado: (2018)

Metabolic Disorders Are Associated With Drug-Induced Liver Injury During Antituberculosis Treatment: A Multicenter Prospective Observational Cohort Study in Korea
por: Lim, Jihye, et al.
Publicado: (2023)

Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India
por: Aruldhas, Blessed Winston, et al.
Publicado: (2019)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
por: Jhun, Byung Woo, et al.
Publicado: (2020)

Fluoroquinolone resistance in multidrug-resistant tuberculosis patients
por: Lee, Hyun-Woo, et al.
Publicado: (2019)

Effects of underweight and overweight on mortality in patients with pulmonary tuberculosis
por: Min, Jinsoo, et al.
Publicado: (2023)

Isoniazid Prophylaxis for Latent Tuberculosis Infections in Liver Transplant Recipients in a Tuberculosis-Endemic Area
por: Moon, Hyung Hwan, et al.
Publicado: (2017)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

Tuberculosis Surveillance and Monitoring under the National Public-Private Mix Tuberculosis Control Project in South Korea 2016–2017
por: Min, Jinsoo, et al.
Publicado: (2020)

Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study
por: Kwak, Se Hyun, et al.
Publicado: (2020)

Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients
por: Lim, Jeong Uk, et al.
Publicado: (2018)

Impact of Combined Chronic Obstructive Pulmonary Disease Status and Systemic Inflammation on Outcome of Advanced NSCLC: Multicenter Retrospective Cohort Study
por: Lim, Jeong Uk, et al.
Publicado: (2020)

Improved Fluoroquinolone-Resistant and Extensively Drug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Eun Hye, et al.
Publicado: (2019)

Clinical profiles of early and tuberculosis-related mortality in South Korea between 2015 and 2017: a cross-sectional study
por: Min, Jinsoo, et al.
Publicado: (2019)

Estimating the burden of nosocomial exposure to tuberculosis in South Korea, a nationwide population based cross-sectional study
por: Kim, Hyung Woo, et al.
Publicado: (2021)

What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis
por: Stagg, H R, et al.
Publicado: (2016)

Rapid Microarray-Based Detection of Rifampin, Isoniazid, and Fluoroquinolone Resistance in Mycobacterium tuberculosis by Use of a Single Cartridge
por: Havlicek, Juliane, et al.
Publicado: (2018)

Isoniazid-Resistant Tuberculosis, Taiwan, 2000–2010
por: Lai, Chih-Cheng, et al.
Publicado: (2011)

Differential effects of sex on tuberculosis location and severity across the lifespan
por: Min, Jinsoo, et al.
Publicado: (2023)

Cluster analysis categorizes five phenotypes of pulmonary tuberculosis
por: Koo, Hyeon-Kyoung, et al.
Publicado: (2022)

Trend of multidrug and fluoroquinolone resistance in Mycobacterium tuberculosis isolates from 2010 to 2014 in Korea: a multicenter study
por: Kim, Hyeonseok, et al.
Publicado: (2019)

A Case of the Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) Following Isoniazid Treatment
por: Lee, Jin-Yong, et al.
Publicado: (2015)

Establishing in vitro and in vivo Co-culture Models of Staphylococcus epidermidis and Enterococcus faecalis to Evaluate the Effect of Topical Fluoroquinolone on Ocular Microbes
por: Kim, Han Woo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ogkot2083rb0f5abib02ra3srd